• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cefepime for Ceftriaxone-Resistant Enterobacterales With Chromosomal AmpC β-Lactamases.

作者信息

Davis Matthew W, Holzworth Abriana C, Rux Caleb E, McManus Dayna, Topal Jeffrey E

机构信息

Department of Pharmacy, Yale-New Haven Hospital, New Haven, Connecticut, USA.

Department of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, USA.

出版信息

Clin Infect Dis. 2023 Jul 5;77(1):162-163. doi: 10.1093/cid/ciad173.

DOI:10.1093/cid/ciad173
PMID:36974628
Abstract
摘要

相似文献

1
Cefepime for Ceftriaxone-Resistant Enterobacterales With Chromosomal AmpC β-Lactamases.
Clin Infect Dis. 2023 Jul 5;77(1):162-163. doi: 10.1093/cid/ciad173.
2
Should cefepime be used for any bloodstream infections caused by ceftriaxone-resistant, cefepime-susceptible Enterobacterales?对于由对头孢曲松耐药但对头孢吡肟敏感的肠杆菌科细菌引起的血流感染，是否应使用头孢吡肟？
Int J Antimicrob Agents. 2023 Sep;62(3):106912. doi: 10.1016/j.ijantimicag.2023.106912. Epub 2023 Jul 5.
3
Effect of ampC derepression on cefepime MIC in Enterobacterales with chromosomally encoded inducible AmpC β-lactamase.染色体介导的诱导型 AmpC β-内酰胺酶对阴沟肠杆菌属中头孢吡肟 MIC 的影响。
Clin Microbiol Infect. 2019 Sep;25(9):1158.e1-1158.e4. doi: 10.1016/j.cmi.2019.05.007. Epub 2019 May 23.
4
Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016-2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam.2016-2018 年期间从美国和欧洲收集的肠杆菌科临床分离株中第三代头孢菌素耐药性：β-内酰胺酶的基因分析和头孢吡肟/恩他唑巴坦的体外比较活性。
J Glob Antimicrob Resist. 2021 Jun;25:93-101. doi: 10.1016/j.jgar.2021.02.031. Epub 2021 Mar 18.
5
In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.大肠杆菌序列型131中CMY-2向CMY-33β-内酰胺酶的体内进化：一种获得性超广谱AmpC对头孢吡肟耐药性的特征分析
Antimicrob Agents Chemother. 2015 Dec;59(12):7483-8. doi: 10.1128/AAC.01804-15. Epub 2015 Sep 21.
6
Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae.临床和实验室标准协会（CLSI）及欧洲抗菌药物敏感性试验委员会（EUCAST）头孢吡肟折点变化对肠杆菌科细菌药敏报告的影响
Diagn Microbiol Infect Dis. 2017 Dec;89(4):328-333. doi: 10.1016/j.diagmicrobio.2017.08.020. Epub 2017 Oct 12.
7
Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain.解析影响碳青霉烯酶产肠杆菌科和耐碳青霉烯铜绿假单胞菌分离株中头孢吡肟-他唑巴坦体外活性的机制：西班牙监测研究中的发现。
Eur J Clin Microbiol Infect Dis. 2024 Feb;43(2):279-296. doi: 10.1007/s10096-023-04697-4. Epub 2023 Dec 2.
8
Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.采用小鼠大腿感染模型，对美罗培南、头孢吡肟或氨曲南与新型β-内酰胺酶抑制剂那库巴坦联合用药，针对耐碳青霉烯类和/或产碳青霉烯酶的肺炎克雷伯菌和大肠埃希菌进行药效学评价。
Int J Antimicrob Agents. 2021 May;57(5):106330. doi: 10.1016/j.ijantimicag.2021.106330. Epub 2021 Mar 28.
9
Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program.头孢吡肟-他唑巴坦与对照药物对 2018 年至 2020 年革兰氏阴性杆菌临床分离株的活性：来自全球抗菌药物耐药性监测计划（GEARS）的结果。
Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0128122. doi: 10.1128/aac.01281-22. Epub 2022 Dec 21.
10
Emerging resistance to ceftriaxone treatment owing to different ampD mutations in Enterobacter roggenkampii.由于产酸克雷伯菌中不同的 ampD 突变导致对头孢曲松治疗的新兴耐药性。
Infect Genet Evol. 2022 Aug;102:105301. doi: 10.1016/j.meegid.2022.105301. Epub 2022 May 11.

引用本文的文献

1
Cefepime versus carbapenem for treating complicated urinary tract infection caused by cefoxitin-nonsusceptible ESCPM organisms: a multicenter, real-world study.头孢吡肟与碳青霉烯类药物治疗由头孢西丁不敏感的肠杆菌科细菌、葡萄球菌和假单胞菌（ESCPM）引起的复杂性尿路感染：一项多中心、真实世界研究
BMC Infect Dis. 2025 Mar 31;25(1):439. doi: 10.1186/s12879-025-10850-5.